EUVIMEDEUVIMED entdecken
Crossref

Translational research in drug development: challenges and opportunities for pharmacists

{"name":"Nageswari Patnam","email":"patnamnageswari05@gmail.com","affiliation":, {"name":"Deep Mukesh Devlekar","email":"patnamnageswari05@gmail.com","affi, {"name":"Arjun Abhijeet Joshi","email":"patnamnageswari05@gmail.com","affil, {"name":"Kanchi Shyam Sawant","email":"patnamnageswari05@gmail.com","affilia, {"name":"Raj Vinayak Patil","email":"patnamnageswari05@gmail.com","affili

Future Journal of Pharmaceuticals and Health Sciences · 07.07.2026 · 6 (3) · 22-31

DOI: 10.26452/fjphs.v6i3.794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 07.07.2026. Verfasst von {"name":"Nageswari Patnam","email":"patnamnageswari05@gmail.com","affiliation": und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Translational Research (TR) constitutes a multidirectional, iterative paradigm designed to facilitate the seamless transition of fundamental biomolecular discoveries into robust clinical interventions. The review critically examines the five - tier (T0 - T4) t ranslational trajectory, identifying the systemic biological and operational bottlenecks - most notably the “Valley of Death” and xenogeneic discordance - that perpetuate the high rates of therapeutic attrition within the pharmaceutical pipeline. Furthermore , it delineates the emergence of the pharmacist as a translational catalyst, uniquely equipped to bridge the gap between abstract molecular hypotheses and patient - centric outcomes through the application of pharmacometrics, Physiologically Based Pharmacoki netic (PBPK) modelling, and Model - Informed Drug Development (MIDD). By integrating multi - modal “omics” data with real - world evidence (RWE), the modern pharmacist optimizes the therapeutic index and ensures the clinical scalability of novel chemical entitie s. This paper posits that a paradigm shift toward Open Science frameworks, systems pharmacology, and precision individualization is imperative for overcoming the epistemological opacity of modern drug discovery and achieving global therapeutic equity.

Zitieren

APA

Patnam","email":"patnamnageswari05@gmail.com","affiliation":, N., Devlekar","email":"patnamnageswari05@gmail.com","affi, N. M., Joshi","email":"patnamnageswari05@gmail.com","affil, N. A., Sawant","email":"patnamnageswari05@gmail.com","affilia, N. S., & Patil","email":"patnamnageswari05@gmail.com","affili, N. V. (2026). Translational research in drug development: challenges and opportunities for pharmacists. Future Journal of Pharmaceuticals and Health Sciences, 6(3), 22-31. https://doi.org/10.26452/fjphs.v6i3.794

Vancouver

Patnam","email":"patnamnageswari05@gmail.com","affiliation": N, Devlekar","email":"patnamnageswari05@gmail.com","affi NM, Joshi","email":"patnamnageswari05@gmail.com","affil NA, Sawant","email":"patnamnageswari05@gmail.com","affilia NS, Patil","email":"patnamnageswari05@gmail.com","affili NV. Translational research in drug development: challenges and opportunities for pharmacists. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(3):22-31. doi:10.26452/fjphs.v6i3.794

BibTeX
@article{Patnamemailpatnamnageswarigmailcomaffiliation2026,
  author = {Patnam","email":"patnamnageswari05@gmail.com","affiliation":, "name":"Nageswari and Devlekar","email":"patnamnageswari05@gmail.com","affi, "name":"Deep Mukesh and Joshi","email":"patnamnageswari05@gmail.com","affil, "name":"Arjun Abhijeet and Sawant","email":"patnamnageswari05@gmail.com","affilia, "name":"Kanchi Shyam and Patil","email":"patnamnageswari05@gmail.com","affili, "name":"Raj Vinayak},
  title = {Translational research in drug development: challenges and opportunities for pharmacists},
  journal = {Future Journal of Pharmaceuticals and Health Sciences},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {22--31},
  doi = {10.26452/fjphs.v6i3.794}
}
Kostenlos starten →